{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:11:06Z","timestamp":1784815866522,"version":"3.55.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psoriasis is a relapsing inflammatory skin disease that significantly impacts patients' quality of life, particularly those with moderate-to-severe lesions, which also impose considerable psychological stress. Biologics have become a primary therapeutic approach for moderate-to-severe plaque psoriasis. This study aims to evaluate the clinical efficacy and safety of biologics, providing guidance for clinical application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Cochrane Library, EMBASE, and Web of Science from inception to May 29, 2024, and conducted an updated supplementary search from May 30, 2024 to April 25, 2026 to identify randomized controlled trials (RCTs) assessing the efficacy and safety of IL-23\/IL-17 inhibitors in treating moderate-to-severe plaque psoriasis. The quality of the included studies was evaluated using the Cochrane risk of bias tool, and a meta-analysis was performed using R software (version 4.3.1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>A total of 23 publications were included after screening, comprising 27 RCTs that were incorporated into the network meta-analysis. The meta-analysis results showed that several regimens, including Guselkumab 200 mg, Secukinumab 300 mg, and Brodalumab 210 mg, ranked highly for PASI 75 and PASI 90 at specific follow-up time points; however, ranking patterns varied across outcomes and follow-up durations. Additionally, Tildrakizumab 100 mg and Tildrakizumab 200 mg showed high SUCRA values for achieving cleared or almost cleared skin and reducing the Dermatology Life Quality Index (DLQI) score at most follow-up time points. In short-term safety analyses, some agents showed a higher incidence of adverse events compared to placebo, including Brodalumab 140 mg at 12 weeks [RR = 1.12, 95%CrI = (1.03, 1.23)] and Secukinumab 150 mg [RR = 1.22, 95% CrI = (1.09, 1.35)]. However, adverse-event reporting was not uniformly comprehensive across all included trials, and these findings should therefore be interpreted with caution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This network meta-analysis provides regimen-specific comparative evidence for short-term efficacy and safety of IL-23\/IL-17 inhibitors. Treatment rankings should be interpreted within each outcome and follow-up time point, together with effect estimates, safety profiles, and the amount of supporting evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO<\/jats:ext-link>\n                      , identifier CRD42024584441.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1766348","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:57:15Z","timestamp":1784815035000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of interleukin inhibitors in the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"June","family":"Ming","sequence":"first","affiliation":[{"name":"Department of Dermatology, Sichuan Provincial Hospital of Traditional Chinese Medicine, Chengdu","place":["Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayi","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Sichuan Provincial Hospital of Traditional Chinese Medicine, Chengdu","place":["Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinyao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sichuan Provincial Hospital of Traditional Chinese Medicine, Chengdu","place":["Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sichuan Provincial Hospital of Traditional Chinese Medicine, Chengdu","place":["Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingling","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sichuan Provincial Hospital of Traditional Chinese Medicine, Chengdu","place":["Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA."},{"key":"B2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"Fitzgerald","year":"2021","journal-title":"Nat Rev Dis Prim"},{"key":"B4","doi-asserted-by":"publisher","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","volume":"64","author":"Langley","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/jdv.15879","article-title":"Biologic therapies targeting the interleukin (IL)-23\/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis","volume":"34","author":"Erichsen","year":"2020","journal-title":"J Euro Acad Dermatol Venereol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1080\/09546634.2021.1914812","article-title":"Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis","volume":"33","author":"Blauvelt","year":"2022","journal-title":"J Dermatol Treat."},{"key":"B8","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/bjd.21743","article-title":"Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)","volume":"187","author":"Blauvelt","year":"2022","journal-title":"Br J Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br J Dermatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/09546634.2019.1587145","article-title":"Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study","volume":"31","author":"Ferris","year":"2020","journal-title":"J Dermatol Treat"},{"key":"B11","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1056\/NEJMoa1501646","article-title":"A Phase 2 trial of guselkumab versus adalimumab for plaque psoriasis","volume":"373","author":"Gordon","year":"2015","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2014 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","article-title":"Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study","volume":"81","author":"Nakagawa","year":"2016","journal-title":"J Dermatol Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s13555-022-00776-0","article-title":"Risankizumab for the treatment of moderate to severe plaque psoriasis in the russian federation","volume":"12","author":"Odnopozova","year":"2022","journal-title":"Dermatol Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/1346-8138.14504","article-title":"Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study","volume":"45","author":"Ohtsuki","year":"2018","journal-title":"J Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/bjd.13932","article-title":"Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/jdv.12751","article-title":"Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE)","volume":"29","author":"Paul","year":"2015","journal-title":"J Euro Acad Dermatol Venereol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s13555-021-00554-4","article-title":"Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial","volume":"11","author":"Puig","year":"2021","journal-title":"Dermatol Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/j.1365-2133.2011.10419.x","article-title":"Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis","volume":"165","author":"Strober","year":"2011","journal-title":"Br J Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1001\/jamaoto.2017.2513","article-title":"Association of age-related hearing loss with cognitive function, cognitive impairment, and dementia: a systematic review and meta-analysis","volume":"144","author":"Loughrey","year":"2018","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1093\/rheumatology\/keab119","article-title":"Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis","volume":"60","author":"Mease","year":"2021","journal-title":"Rheumatology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2546161","DOI":"10.1155\/2019\/2546161","article-title":"Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials","volume":"2019","author":"Bai","year":"2019","journal-title":"J Immunol Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000077660","article-title":"T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action","volume":"208","author":"Jullien","year":"2004","journal-title":"Dermatology."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1084\/jem.20060244","article-title":"IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis","volume":"203","author":"Chan","year":"2006","journal-title":"J Exp Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"E3422","DOI":"10.1073\/pnas.1400513111","article-title":"IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms","volume":"111","author":"Ha","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B36","doi-asserted-by":"publisher","first-page":"487","DOI":"10.36849\/JDD.2020.4957","article-title":"Importance of complete skin clearance in psoriasis as a treatment goal: implications for patient-reported outcomes","volume":"19","author":"Blauvelt","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00403-022-02420-5","article-title":"The impact of complete clearance and almost complete clearance of psoriasis on quality of life: a literature review","volume":"315","author":"Boswell","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1080\/1744666X.2018.1401468","article-title":"The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis","volume":"14","author":"Frieder","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.intimp.2018.08.039","article-title":"Corrigendum to \u201cEfficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials\u201d [Int. Immunopharmacol. 62 (2018) 46\u201358]","volume":"64","author":"Cui","year":"2018","journal-title":"Int Immunopharmacol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1766348\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:57:17Z","timestamp":1784815037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1766348\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":39,"alternative-id":["10.3389\/fmed.2026.1766348"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1766348","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"1766348"}}